SCHEDULE: Rosalind Advisors Discloses Fennec Pharmaceuticals Stake

Rosalind Advisors Inc. and related entities have reported beneficial ownership of approximately 8.8% of Fennec Pharmaceuticals Inc. common shares as of March 31, 2026.

Summary

• Rosalind Advisors Inc., along with Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon, have filed a Schedule 13G, indicating their beneficial ownership of Fennec Pharmaceuticals Inc. common shares.
• As of March 31, 2026, Rosalind Advisors Inc. beneficially owns 3,041,533 shares, representing 8.8% of the class.
• Rosalind Master Fund L.P. beneficially owns 2,908,201 shares, representing 8.4% of the class.
• Steven Salamon and Gilad Aharon each beneficially own 2,974,867 shares, representing 8.6% of the class.
• The total outstanding ordinary shares of Fennec Pharmaceuticals Inc. were 34,712,756 as of April 13, 2026.
• Rosalind Advisors Inc. acts as the investment advisor to Rosalind Master Fund L.P.
• Steven Salamon is the portfolio manager for Rosalind Advisors Inc., and Gilad Aharon is also a portfolio manager and member of Rosalind Advisors Inc.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports on ownership stakes and does not provide operational or financial performance data, making it informative for understanding investor positions but not for assessing company performance.

Positives

• Significant stake held by a recognized investment advisor, potentially indicating confidence in the company's prospects.
• The filing is an amendment to a previous filing, suggesting ongoing investment activity and monitoring.
• The reporting persons disclaim beneficial ownership of shares beyond their advisory roles, clarifying their specific interests.

Negatives

• The filing does not contain specific financial performance data or operational updates, focusing solely on ownership.
• The disclaimers of beneficial ownership by Rosalind Advisors Inc. and Steven Salamon, while standard, can introduce a layer of complexity in interpreting their ultimate control or intent.

Risks

• Potential for increased market activity or influence by Rosalind Advisors Inc. given their substantial stake.
• The filing does not detail specific risks associated with Fennec Pharmaceuticals Inc., as it is a Schedule 13G focused on ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Fennec Pharmaceuticals Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• Rosalind Advisors Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.
• Steven Salamon is the portfolio manager of the Advisor which advises RMF.
• Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.
• Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment advisors accumulating significant stakes in publicly traded companies. This filing indicates a notable investment position in Fennec Pharmaceuticals by Rosalind Advisors and its associated entities, which could signal their belief in the company's value or strategic direction within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant ownership block, which can influence market perception and potential future corporate actions.
• Management of Fennec Pharmaceuticals Inc.: Awareness of substantial ownership by Rosalind Advisors Inc. may inform strategic discussions and governance considerations.

Next Steps

• Continued monitoring of Fennec Pharmaceuticals Inc. by Rosalind Advisors Inc. and associated entities.
• Potential for further filings if ownership levels change significantly.

Key Dates

Keywords

Fennec Pharmaceuticals, Schedule 13G, Rosalind Advisors, Rosalind Master Fund, Steven Salamon, Gilad Aharon, Beneficial Ownership, Common Shares, Investment Advisor, SEC Filing